BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhattacharya A, Rao BB, Koutroubakis IE, Click B, Vargas EJ, Regueiro M, Schwartz M, Swoger JM, Babichenko D, Hartmann D, Rivers CR, Barrie A, Hashash JG, Dunn MA, Binion DG. Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up: The Consequences of Under-reporting Active Inflammation. Inflamm Bowel Dis. 2016;22:2665-2671. [PMID: 27753691 DOI: 10.1097/mib.0000000000000935] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Click B, Barnes EL, Cohen BL, Sands BE, Hanson JS, Rubin DT, Dubinsky MC, Regueiro M, Gazis D, Crawford JM, Long MD. Objective disease activity assessment and therapeutic drug monitoring prior to biologic therapy changes in routine inflammatory bowel disease clinical practice: TARGET-IBD. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02143-x] [Reference Citation Analysis]
2 Yao JY, Jiang Y, Ke J, Lu Y, Hu J, Zhi M. Development of a prognostic model for one-year surgery risk in Crohn’s disease patients: A retrospective study. World J Gastroenterol 2020; 26(5): 524-534 [PMID: 32089628 DOI: 10.3748/wjg.v26.i5.524] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Rozendorn N, Amitai MM, Eliakim RA, Kopylov U, Klang E. A review of magnetic resonance enterography-based indices for quantification of Crohn's disease inflammation. Therap Adv Gastroenterol 2018;11:1756284818765956. [PMID: 29686731 DOI: 10.1177/1756284818765956] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
4 Pagnini C, Mariani MB, Corleto VD, Delle Fave G. Elevated C-Reactive Protein in Asymptomatic Crohn's Disease Patients: Listen to the Sound of Silence. Inflamm Bowel Dis 2017;23:E13. [PMID: 28146005 DOI: 10.1097/MIB.0000000000001030] [Reference Citation Analysis]
5 Watanabe K. Clinical management for small bowel of Crohn's disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. Intest Res. 2020;18:347-354. [PMID: 33131231 DOI: 10.5217/ir.2020.00032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022:S0016-5085(21)04072-5. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
7 Burisch J, Bergemalm D, Halfvarson J, Domislovic V, Krznaric Z, Goldis A, Dahlerup JF, Oksanen P, Collin P, de Castro L, Hernandez V, Turcan S, Belousova E, D'Incà R, Sartini A, Valpiani D, Giannotta M, Misra R, Arebi N, Duricova D, Bortlik M, Gatt K, Ellul P, Pedersen N, Kjeldsen J, Andersen KW, Andersen V, Katsanos KH, Christodoulou DK, Sebastian S, Barros L, Magro F, Midjord JM, Nielsen KR, Salupere R, Kievit HA, Kiudelis G, Kupčinskas J, Fumery M, Gower-Rousseau C, Kaimakliotis IP, Schwartz D, Odes S, Lakatos L, Lakatos PL, Langholz E, Munkholm P; Epi-IBD group. The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study. United European Gastroenterol J 2020;8:949-60. [PMID: 32715989 DOI: 10.1177/2050640620945949] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
8 Coates MD, Soriano C, Dalessio S, Stuart A, Walter V, Koltun W, Bernasko N, Tinsley A, Clarke K, Williams ED. Gastrointestinal hypoalgesia in inflammatory bowel disease. Ann Gastroenterol 2020;33:45-52. [PMID: 31892797 DOI: 10.20524/aog.2019.0442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Panchal H, Wagner M, Chatterji M, Taouli B, McBride R, Patterson JR, Ungaro R, Dubinsky M, Cho J, Sachar DB. Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage. Dig Dis Sci 2019;64:3274-83. [PMID: 30607690 DOI: 10.1007/s10620-018-5434-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]